The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L04 | Immunosuppressants | |
| 3 | L04A | Immunosuppressants | |
| 4 | L04AK |
| Code | Title | |
|---|---|---|
| L04AK01 | Leflunomide | |
| L04AK02 |
| Active Ingredient | Description | |
|---|---|---|
| Leflunomide |
Leflunomide is a disease-modifying anti-rheumatic agent with antiproliferative properties. A771726, the active metabolite of leflunomide, inhibits the human enzyme dihydroorotate dehydrogenase (DHODH) and exhibits antiproliferative activity. |
|
| Teriflunomide |
Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), required for the de novo pyrimidine synthesis. As a consequence teriflunomide reduces the proliferation of dividing cells that need de novo synthesis of pyrimidine to expand. The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is not fully understood, but this is mediated by a reduced number of lymphocytes. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ARAVA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| AUBAGIO Film-coated tablets | European Medicines Agency (EU) | MPI, EU: SmPC |
